Abstract
The compounds described are potent, orally active inhibitors of the release of the leukotriene mediators of anaphylaxis in vitro and in vivo. Unlike most “Mediator Release Inhibitors” (MRI's) described in the literature, they do not contain an acidic function. A series of potent, orally-active inhibitors of leukotriene release has been synthesized and tested in vitro and in vivo. The effects of ring size and substituents on anti-allergic activity have been examined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
